Proactiveinvestors recommends

Additional Information

Market:	AIM
Sector:	Chemicals
EPIC:	PIM
Latest Price:	17.00 (3.03% )
52-week High:	32.50
52-week Low:	15.25
Market Cap:	8.56M

1 year chart

1 day chart

Plant Impact Full Plant Impact profile here

Plant Impact's range of crop nutrition products focus on crop enhancement. They improve crop performance and crop health giving growers increased marketable yields, better quality and longer shelf life with reduced environmental impact.

Plant Impact enters exclusive evaluation, development and distribution deal with Arysta

Monday, February 08, 2010

Plant Impact (AIM: PIM) has announced an exclusive evaluation, development and distribution agreement with Arysta LifeScience Corp covering its InCa, Balance and Cocoa Stress Tolerance products, extending Plant Impact’s territorial coverage from 24 to 52 countries.

The deal will also increase field trial development of the Crop Nutrient Products as Arysta is planning some 350 field trials over the next 12 to 18 months, resulting in more than 500 field trials being conducted, thus lifting the products’ commercial potential.

Under the agreement, which covers countries in North America, Central and Latin America, Europe, Africa and the Far East, Arysta will have exclusivity to evaluate the products until 31 March 2011, after will the company will register, market and distribute the products on an exclusive basis.

“Agriculture is challenged to feed the world during a time when the population is increasing and natural resources are decreasing. We firmly believe that new science and technologies that are sustainable, environmentally safe, which increase crop marketable yield and yet are able to decrease wastage and conserve natural resources are the way forward. Plant Impact has such science and technologies. With this agreement our company has significantly expanded its route to market and continues to prove efficacy and commercial viability,” said Chief Executive of Plant Impact Pete Blezard.

Plant Impact reported on its interim results last month, saying that revenues amounted to £969,554 compared to £225,287 for the equivalent period of the previous year, while losses narrowed to £879,381 from £1.3 million a year ago. The increase in revenues was largely due to the sales of nutrient products in the US and milestone payments for pesticide product BugOil after the company entered into a licensing agreement with Arysta.

Plant Impact has also signed an extramural agreement with the United States Department of Agriculture (USDA) for extensive trials on its nitrogen delivery technology PiNT. The company has recently been appointed as a member of the parliamentary science committee to the UK House of Commons and its work with the USDA, which it said was key to the widespread commercialisation of its products.

Earlier this month, Plant Impact reported positive results of the studies of its PiNT technology, aimed at enabling higher yielding stronger plantsPiNT, conducted by the US Department of Agriculture (USDA), which it said enabled it to further penetrate a lucrative market.

Investment research company Equity Development Research issued a note on the company in December, noting what it said was “significant progress in terms of commercializing key technologies over the past six months” and maintaining its price target of 60 pence for the stock.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.